Evolve's Dr. Bethany Henrick to speak at the European Microbiome Congress

Evolve BioSystems is pleased to announce that our Director of Immunology & Diagnostics, Dr. Bethany Henrick, will be speaking at the 3rd Annual European Microbiome Congress on November 28th in London.

Dr. Henrick will be presenting our latest research on the infant gut microbiome, in a talk titled "Providing and Maintaining a Healthy Microbiome in All Infants During the First 6 Months of Life…a new paradigm in infant nutrition."

The 3rd Annual European Microbiome Congress has become a trusted learning and networking platform for leading academics, practicing clinicians, pharmaceutical and nutrition companies, biotech entrepreneurs and investors, government and regulatory bodies and industry leaders who require insight into the latest microbiome research, clinical trials and multi-disciplinary collaborations.

For more details on the event, click here

To learn more about Evolve BioSystems, visit us at evolvebiosystems.com

Evolve BioSystems Contact
Dr. Tracy Shafizadeh
Director, Scientific Communications
tshafizadeh@evolvebiosystems.com

About Evolve BioSystems
Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve’s discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering.  In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs.

Tracy Shafizadeh